Evaluation of drug transporter interactions in drug discovery and development

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 2, 2010, Pages 112-134

  Lai, Yurong ^a   Sampson, Kathleen E ^a   Stevens, Jeffrey C ^a  

^a PFIZER INC   (United States)

Author keywords

Absorption; Assay development; Drug disposition; Drug transporters; Drug drug interaction; High throughput screening; Pharmacokinetics; Preclinical models

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PEPTIDE TRANSPORTER 1;

BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG PENETRATION; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; GENE FUNCTION; GENE LOCATION; HEPATOBILIARY SYSTEM; HIGH THROUGHPUT SCREENING; INTESTINE ABSORPTION; KIDNEY TUBULE EXCRETION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TRANSPORT KINETICS;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 77949866584     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790596772     Document Type: Review

References (271)

1. Bachmann, K.A.R.; J.B.; Wrighton, S.A. Cytochrome P450 and its place in drug discovery and development. In: Lee JO, S.R.; Fisher, M.B., ed. Drug metabolizing enzymes. New York: Marcel Dikker, 2003, 311-332.
2. Holtzman, C.W.; Wiggins, B.S.; Spinler S.A. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy, 2006, 26, 1601-1607.
3. Huang, S.M.; Temple R.; Throckmorton, D.C.; Lesko, L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther., 2007, 81, 298-304.
4. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta., 1999, 1461, 347-357.
5. Schinkel, A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol., 1997, 8, 161-170.
6. Xia, C.Q.; Yang, J.J.; Gan, L.S. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin. Drug Metab. Toxicol., 2005, 1, 595-611.
7. Byrne, J.A.; Strautnieks, S.S.; Mieli-Vergani, G.; Higgins, C.F.; Linton, K.J.; Thompson, R.J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology, 2002, 123, 1649-1658.
8. Lee, J.M.; Trauner, M.; Soroka, C.J.; Stieger, B.; Meier, P.J.; Boyer, J.L. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology, 2000, 118, 163-172.
9. Lautier, D.; Canitrot, Y.; Deeley, R.G.; Cole, S.P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol., 1996, 52, 967-977.
10. Litman, T.; Druley, T.E.; Stein, W.D.; Bates, S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci., 2001, 58, 931-959.
11. Burckhardt, G.; Wolff, N.A. Structure of renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol., 2000, 278, F853-F866.
12. Dresser, M.J.; Leabman, M.K.; Giacomini, K.M. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci., 2001, 90, 397-421.
13. Dean, M.; Allikmets, R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr., 2001, 33, 475-479.
14. Gottesman, M.M.; Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett., 2006, 580, 998-1009.
15. Cundy, K.C.; Branch, R.; Chernov-Rogan, T.; Dias, T.; Estrada, T.; Hold, K.; Koller, K.; Liu, X.; Mann, A.; Panuwat, M.; Raillard, S.P.; Upadhyay, S.; Wu, Q.Q.; Xiang, J.N.; Yan, H.; Zerangue, N.; Zhou, C.X.; Barrett, R.W.; Gallop, M.A. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther., 2004, 311, 315-323.
16. Ezra, A.; Hoffman, A.; Breuer, E.; Alferiev, I.S.; Monkkonen, J.; El Hanany-Rozen, N.; Weiss, G.; Stepensky, D.; Gati, I.; Cohen, H.; Tormalehto, S.; Amidon, G.L.; Golomb, G. A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem., 2000, 43, 3641-3652.
17. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 2006, 27, 425-446.
18. Calcagno, A.M.; Kim, I.W.; Wu, C.P.; Shukla, S.; Ambudkar, S.V. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr. Drug Deliv., 2007, 4, 324-333.
19. Lennernas, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica., 2007, 37, 1015-1051.
20. Lennernas, H. Intestinal drug absorption and bioavailability: beyond involvement of single transport function. J. Pharm. Pharmacol., 2003, 55, 429-433.
21. Kunta, J.R.; Sinko, P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab., 2004, 5, 109-124.
22. Collett, A.; Stephens, R.H.; Harwood, M.D.; Humphrey, M.; Dallman, L.; Bennett, J.; Davis, J.; Carlson, G.L.; Warhurst, G. Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5- methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption. Drug Metab. Dispos., 2008, 36, 87-94.
23. Higgins, C.F. ABC transporters: physiology, structure and mechanism--an overview. Res. Microbiol., 2001, 152, 205-210.
24. Tanaka, Y.; Slitt, A.L.; Leazer, T.M.; Maher, J.M.; Klaassen, C.D. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem. Biophys. Res. Commun., 2005, 326, 181-187.
25. Dietrich, C.G.; Geier, A.; Oude Elferink, R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut, 2003, 52, 1788-1795.
26. Dano, K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta., 1973, 323, 466-483.
27. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta., 1976, 455, 152-162.
28. Wacher, V.J.; Wu, C.Y.; Benet, L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 1995, 13, 129-134.
29. Fromm, M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther., 2000, 38, 69-74.
30. Suzuki, H.; Sugiyama, Y. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin. Liver Dis., 1998, 18, 359-376.
31. Keppler, D.; Konig, J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis., 2000, 20, 265-272.
32. Fardel, O.; Jigorel, E.; Le Vee, M.; Payen, L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed. Pharmacother., 2005, 59, 104-114.
33. Cui Y.; Konig J.; Buchholz J.K.; Spring H.; Leier I.; Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55, 929-937.
34. Kusuhara, H.; Sugiyama, Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control Release, 2002, 78, 43-54.
35. Rocchi, E.; Khodjakov, A.; Volk, E.L.; Yang, C.H.; Litman, T.; Bates, S.E.; Schneider, E. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun., 2000, 271, 42-46.
36. Jonker, J.W.; Smit, J.W.; Brinkhuis, R.F.; Maliepaard, M.; Beijnen, J.H.; Schellens, J.H.; Schinkel, A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92, 1651-1656.
37. Jonker, J.W.; Buitelaar, M.; Wagenaar, E.; Van Der Valk, M.A.; Scheffer, G.L.; Scheper, R.J.; Plosch, T.; Kuipers, F.; Elferink, R.P.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA, 2002, 99, 15649-15654.
38. Merino, G.; Jonker, J.W.; Wagenaar, E.; van Herwaarden, A.E.; Schinkel, A.H. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol., 2005, 67, 1758-1764.
39. Tamai, I.; Ogihara, T.; Takanaga, H.; Maeda, H.; Tsuji, A. Anion antiport mechanism is involved in transport of lactic acid across intestinal epithelial brush-border membrane. Biochim. Biophys. Acta., 2000, 1468, 285-292.
40. Kullak-Ublick, G.A.; Becker, M.B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev., 2003, 35, 305-317.
41. Walters, H.C.; Craddock, A.L.; Fusegawa, H.; Willingham, M.C.; Dawson, P.A. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279, G1188-G1200.
42. Swaan, P.W.; Tukker, J.J. Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci., 1997, 86, 596-602.
43. Inui, K.; Terada, T.; Masuda, S.; Saito, H. Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant., 2000, 15(Suppl 6), 11-13.
44. Cundy, K.C.; Annamalai, T.; Bu, L.; De Vera, J.; Estrela, J.; Luo, W.; Shirsat, P.; Torneros, A.; Yao, F.; Zou, J.; Barrett, R.W.; Gallop, M.A. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther., 2004, 311, 324-333.
45. Chiou, W.L.; Chung, S.M.; Wu, T.C.; Ma, C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther., 2001, 39, 93-101.
46. Hochman, J.H.; Yamazaki, M.; Ohe, T.; Lin, J.H. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr. Drug Metab., 2002, 3, 257-273.
47. Lin, J.H.; Yamazaki, M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev., 2003, 35, 417-454.
48. Hochman, J.H.; Pudvah, N.; Qiu, J.; Yamazaki, M.; Tang, C.; Lin, J.H.; Prueksaritanont, T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res., 2004, 21, 1686-1691.
49. Robertson, E.E.; Rankin, G.O. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther., 2006, 109, 399-412.
50. Uwai, Y.; Ida, H.; Tsuji, Y.; Katsura, T.; Inui, K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res., 2007, 24, 811-815.
51. Li, M.; Anderson, G.D.; Phillips, B.R.; Kong, W.; Shen, D.D.; Wang, J. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab. Dispos., 2006, 34, 547-555.
52. Lee, W.; Kim, R.B. Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 137-166.
53. Ahn, D.W.; Chung, J.M.; Kim, J.Y.; Kim, K.R.; Park, Y.S. Inhibition of renal Na+/H+ exchange in cadmium-intoxicated rats. Toxicol. Appl. Pharmacol., 2005, 204, 91-98
54. Huls, M.; van den Heuvel, J.J.; Dijkman, H.B.; Russel, F.G.; Masereeuw, R. ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney. Kidney Int., 2006, 69, 2186-2193.
55. Huls, M.; Brown, C.D.; Windass, A.S.; Sayer, R.; van den Heuvel, J.J.; Heemskerk, S.; Russel, F.G.; Masereeuw, R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int., 2008, 73, 220-225.
56. Bendayan, R. Renal drug transport: a review. Pharmacotherapy, 1996, 16, 971-985.
57. Izzedine, H.; Launay-Vacher, V.; Deray, G. Renal tubular transporters and antiviral drugs: an update. Aids, 2005, 19, 455-462.
58. Ueo, H.; Motohashi, H.; Katsura, T.; Inui, K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol., 2005, 70, 1104-1113.
59. Cundy, K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet., 1999, 36, 127-143.
60. Fujita, T.; Urban, T.J.; Leabman, M.K.; Fujita, K.; Giacomini, K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci., 2006, 95, 25-36.
61. Wright, S.H.; Dantzler, W.H. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev., 2004, 84, 987-1049.
62. Kimura, N.; Okuda, M.; Inui, K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res., 2005, 22, 255-259.
63. Dresser, M.J.; Xiao, G.; Leabman, M.K.; Gray, A.T.; Giacomini, K.M. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res., 2002, 19, 1244-1247.
64. Kimura, N.; Masuda, S.; Tanihara, Y.; Ueo, H.; Okuda, M.; Katsura, T.; Inui, K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet., 2005, 20, 379-386.
65. Somogyi, A. Renal transport of drugs: specificity and molecular mechanisms. Clin. Exp. Pharmacol. Physiol., 1996, 23, 986-989.
66. Somogyi A.; Muirhead M. Pharmacokinetic interactions of cimetidine 1987. Clin. Pharmacokinet., 1987, 12, 321-366.
67. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci., 1992, 17, 463-468.
68. Morrow, C.S.; Smitherman, P.K.; Townsend, A.J. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog., 2000, 29, 170-178.
69. Meier, P.J.; Eckhardt, U.; Schroeder, A.; Hagenbuch, B.; Stieger, B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology, 1997, 26, 1667-1677.
70. Kusuhara, H.; Suzuki, H.; Sugiyama, Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci., 1998, 87, 1025-1040.
71. Hooiveld, G.J.; van Montfoort, J.E.; Meijer, D.K.; Muller, M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur. J. Pharm. Sci., 2001, 12, 525-543.
72. Chandra, P.; Brouwer, K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res., 2004, 21, 719-735.
73. Ishikawa, T.; Akimaru, K.; Kuo, M.T.; Priebe, W.; Suzuki, M. How does the MRP/GS-X pump export doxorubicin? J. Natl. Cancer Inst., 1995, 87, 1639-1640.
74. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 278, G156-G164.
75. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 2000, 275, 23161-23168.
76. Kullak-Ublick, G.A.; Ismair, M.G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P.J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 2001, 120, 525-533.
77. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W.P.; Kirchgessner, T.G. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem., 1999, 274, 37161-37168.
78. Kopplow, K.; Letschert, K.; Konig, J.; Walter, B.; Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol., 2005, 68, 1031-1038.
79. Ho, R.H.; Tirona, R.G.; Leake, B.F.; Glaeser, H.; Lee, W.; Lemke, C.J.; Wang, Y.; Kim, R.B. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology, 2006, 130, 1793-1806.
80. Nezasa, K.; Higaki, K.; Takeuchi, M.; Nakano, M.; Koike, M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica., 2003, 33, 379-388.
81. Hirano, M.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther., 2004, 311, 139-146.
82. Sai, Y.; Tsuji, A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov. Today, 2004, 9, 712-720.
83. Zhang, Y.; Benet. L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40, 159-168.
84. Smith, N.F.; Figg, W.D.; Sparreboom, A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol., 2005, 1, 429-445.
85. Lau, Y.Y.; Huang, Y.; Frassetto, L.; Benet, L.Z. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther., 2007, 81, 194-204.
86. Poirier, A.; Funk, C.; Lave, T.; Noe, J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discov. Devel., 2007, 10, 74-83.
87. Muck, W.; Mai, I.; Fritsche, L.; Ochmann, K.; Rohde, G.; Unger, S.; Johne, A.; Bauer, S.; Budde, K.; Roots, I.; Neumayer, H.H.; Kuhlmann, J. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther., 1999, 65, 251-261.
88. Shitara, Y.; Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther., 2006, 112, 71-105.
89. Kamimoto, Y.; Gatmaitan, Z.; Hsu, J.; Arias, I.M. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem., 1989, 264, 11693-11698.
90. Schinkel, A.H.; Mol, C.A.; Wagenaar, E.; van Deemter, L.; Smit, J.J.; Borst, P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer, 1995, 31A, 1295-1298.
91. Smit, J.J.; Schinkel, A.H.; Oude Elferink, R.P.; Groen, A.K.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; Ottenhoff, R.; van der Lugt, N.M.; van Roon, M.A.; Van der Valk, M.A.; Offerhaus, G.J.A.; Berns, A.J.M.; Borst, P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 1993, 75, 451-462.
92. Paulusma, C.C.; van Geer, M.A.; Evers, R.; Heijn, M.; Ottenhoff, R.; Borst, P.; Oude Elferink, R.P. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates lowaffinity transport of reduced glutathione. Biochem. J., 1999, 338 (Pt 2), 393-401.
93. Keppler, D.; Arias, I.M. Hepatic canalicular membrane. Introduction: transport across the hepatocyte canalicular membrane. FASEB J., 1997, 11, 15-18.
94. Ito, K.; Suzuki, H.; Hirohashi, T.; Kume, K.; Shimizu, T.; Sugiyama, Y. Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem., 1998, 273, 1684-1688.
95. Konig, J.; Nies, A.T.; Cui, Y.; Leier, I.; Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta., 1999, 1461, 377-394.
96. Naruhashi, K.; Tamai, I.; Inoue, N.; Muraoka, H.; Sai, Y.; Suzuki, N.; Tsuji, A. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob. Agents Chemother., 2002, 46, 344-349.
97. Suzuki, H.; Sugiyama, Y. Transporters for bile acids and organic anions. Pharm. Biotechnol., 1999, 12, 387-439.
98. Tian, X.; Zamek-Gliszczynski, M.J.; Li, J.; Bridges, A.S.; Nezasa, K.; Patel, N.J.; Raub, T.J.; Brouwer, K.L. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab. Dispos., 2008, 36, 61-64.
99. Maier-Salamon, A.; Hagenauer, B.; Reznicek, G.; Szekeres, T.; Thalhammer, T.; Jager, W. Metabolism and disposition of resveratrol in the isolated perfused rat liver: Role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci., 2008, 97, 1615-1628.
100. Allikmets, R.; Schriml, L.M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 1998, 58, 5337-5339.
101. Suzuki, M.; Suzuki, H.; Sugimoto, Y.; Sugiyama, Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem., 2003, 278, 22644-22649.
102. Hirano, M.; Maeda, K.; Matsushima, S.; Nozaki, Y.; Kusuhara, H.; Sugiyama, Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 2005, 68, 800-807.
103. Merino, G.; van Herwaarden, A.E.; Wagenaar, E.; Jonker, J.W.; Schinkel, A.H. Gender-dependent expression and activity of the ABC transporter Breast Cancer Resistance Protein (BCRP/ABC G2) in liver. Mol. Pharmacol., 2005, 67, 1765.
104. Zamek-Gliszczynski, M.J.; Hoffmaster, K.A.; Humphreys, J.E.; Tian, X.; Nezasa, K.; Brouwer, K.L. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther., 2006, 319, 459-467.
105. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab. Dispos., 2007, 35, 209-214.
106. Kullak-Ublick, G.A.; Beuers, U.; Paumgartner, G. Hepatobiliary transport. J. Hepatol., 2000, 32, 3-18.
107. Wang, E.J.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm. Res., 2003, 20, 537-544.
108. Funk, C.; Pantze, M.; Jehle, L.; Ponelle, C.; Scheuermann. G.; Lazendic. M.; Gasser, R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology, 2001, 167, 83-98.
109. Funk, C.; Ponelle, C.; Scheuermann, G.; Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol., 2001, 59, 627-635.
110. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G.A.; Meier, P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology, 2000, 118, 422-430.
111. Bolder, U.; Trang, N.V.; Hagey, L.R.; Schteingart, C.D.; Ton-Nu, H.T.; Cerre, C.; Elferink, R.P.; Hofmann, A.F. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology, 1999, 117, 962-971.
112. Sakurai, A.; Kurata, A.; Onishi, Y.; Hirano, H.; Ishikawa, T. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf., 2007, 6, 71-86.
113. Ohtsuki, S. New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system. Biol. Pharm. Bull, 2004, 27, 1489-1496.
114. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res., 2007, 24, 1745-1758.
115. Alavijeh, M.S.; Chishty, M.; Qaiser, M.Z.; Palmer, A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. Neuro.Rx., 2005, 2, 554-571.
116. Bart, J.; Groen, H.J.; Hendrikse, N.H.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev., 2000, 26, 449-462.
117. Bendayan, R.; Ronaldson, P.T.; Gingras, D.; Bendayan, M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J. Histochem. Cytochem., 2006, 54, 1159-1167.
118. Bihorel, S.; Camenisch, G.; Lemaire, M.; Scherrmann, J.M. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J. Neurochem., 2007, 102, 1749-1757.
119. Schinkel, A.H.; Smit, J.J.; van Tellingen, O.; Beijnen, J.H.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; van der Valk, M.A.; Robanus-Maandag, E.C.; te Riele H.P.J.; Berns A.J.M.; Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
120. Ohtsuki, S.; Yamaguchi, H.; Asashima, T.; Terasaki, T. Establishing a method to isolate rat brain capillary endothelial cells by magnetic cell sorting and dominant mRNA expression of multidrug resistance-associated protein 1 and 4 in highly purified rat brain capillary endothelial cells. Pharm. Res., 2007, 24, 688-694.
121. Kusch-Poddar, M.; Drewe, J.; Fux, I.; Gutmann, H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Res., 2005, 1064, 21-31.
122. Leggas, M.; Adachi, M.; Scheffer, G.L.; Sun, D.; Wielinga, P.; Du, G.; Mercer, K.E.; Zhuang, Y.; Panetta, J.C.; Johnston, B.; Scheper, R.J.; Stewart, C.F.; Schuetz, J.D. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell Biol., 2004, 24, 7612-7621.
123. Cooray, H.C.; Blackmore, C.G.; Maskell, L.; Barrand, M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport., 2002, 13, 2059-2063.
124. Hori, S.; Ohtsuki, S.; Tachikawa, M.; Kimura, N.; Kondo, T.; Watanabe, M.; Nakashima, E.; Terasaki, T. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J. Neurochem., 2004, 90, 526-536.
125. Tachikawa, M.; Watanabe, M.; Hori, S.; Fukaya, M.; Ohtsuki, S.; Asashima, T.; Terasaki, T. Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J. Neurochem., 2005, 95, 294-304.
126. Tamai, I.; Tsuji, A.; Kin, Y. Carrier-mediated transport of cefixime, a new cephalosporin antibiotic, via an organic anion transport system in the rat renal brush-border membrane. J. Pharmacol. Exp. Ther., 1988, 246, 338-344.
127. Yasumiba, S.; Tazuma, S.; Ochi, H.; Chayama, K.; Kajiyama, G. Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats. Biochem. J., 2001, 354, 591-596.
128. Aslamkhan, A.; Han, Y.H.; Walden, R.; Sweet, D.H.; Pritchard, J.B. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am. J. Physiol. Renal Physiol., 2003, 285, F775-F783.
129. Imaoka, T.; Kusuhara, H.; Adachi, M.; Schuetz, J.D.; Takeuchi, K.; Sugiyama, Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol., 2007, 71, 619-627.
130. Tabas, L.B.; Dantzig, A.H. A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles. Anal. Biochem., 2002, 310, 61-66.
131. Xia, C.Q.; Liu, N.; Miwa, G.T.; Gan, L.S. Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab. Dispos., 2007, 35, 576-582.
132. Iannoli, P.; Miller, J.H.; Wang, H.T.; Bode, B.; Souba, W.W.; Avissar, N.E.; Sax, H.C. Characterization of L-leucine transport system in brush border membranes from human and rabbit small intestine. Metabolism, 1999, 48, 1432-1436.
133. Schaefer, M.; Roots, I.; Gerloff, T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet. Genomics, 2006, 16, 855-861.
134. Sarkadi, B.; Price, E.M.; Boucher, R.C.; Germann, U.A.; Scarborough, G.A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem., 1992, 267, 4854-4858.
135. Ambudkar, S.V.; Lelong, I.H.; Zhang, J.; Cardarelli, C.O.; Gottesman, M.M.; Pastan, I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA, 1992, 89, 8472-8476.
136. Drueckes, P.; Schinzel, R.; Palm, D. Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal. Biochem., 1995, 230, 173-177.
137. Sauna, Z.E.; Smith, M.M.; Muller, M.; Kerr, K.M.; Ambudkar, S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr., 2001, 33, 481-491.
138. Garrigues, A.; Nugier, J.; Orlowski, S.; Ezan, E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal. Biochem., 2002, 305, 106-114.
139. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
140. Markowitz, J.S.; Devane, C.L.; Liston, H.L.; Boulton, D.W.; Risch, S.C. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin. Pharmacol. Ther., 2002, 71, 30-38.
141. Polli, J.W.; Wring, S.A.; Humphreys, J.E.; Huang, L.; Morgan, J.B.; Webster, L.O., Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 2001, 299, 620-628.
142. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W.D. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta., 1997, 1361, 169-176.
143. Tolle-Sander, S.; Grill A.; Joshi, H.; Kapil, R.; Persiani, S.; Polli, J.E. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. J. Pharm. Sci., 2003, 92, 1968-1980.
144. Janiszewski, J.S.; Rogers, K.J.; Whalen, K.M.; Cole, M.J.; Liston, T.E.; Duchoslav, E.; Fouda, H.G. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal. Chem., 2001, 73, 1495-1501.
145. Xiao, Y.; Davidson, R.; Smith, A.; Pereira, D.; Zhao, S.; Soglia, J.; Gebhard, D.; de Morais, S.; Duignan, D.B. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol. Pharm., 2006, 3, 45-54.
146. Balimane, P.V.; Pace, E.; Chong, S.; Zhu, M.; Jemal, M.; Pelt, C.K. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. J. Pharm. Biomed. Anal., 2005, 39, 8-16.
147. Irvine, J.D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J.W.; Selick, H.E.; Grove, J.R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci., 1999, 88, 28-33.
148. Franke, H.; Galla, H.; Beuckmann, C.T. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Brain Res. Protoc., 2000, 5, 248-256.
149. Putnam, W.S.; Pan, L.; Tsutsui, K.; Takahashi, L.; Benet, L.Z. Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm. Res., 2002, 19, 27-33.
150. Bakos, E.; Evers, R.; Szakacs, G.; Tusnady, G.E.; Welker, E.; Szabo, K.; de Haas, M.; van Deemter, L.; Borst, P.; Varadi, A.; Sarkadi, B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem., 1998, 273, 32167-32175.
151. Evers, R.; Zaman, G.J.; van Deemter, L.; Jansen, H.; Calafat, J.; Oomen, L.C.; Oude Elferink, R.P.; Borst, P.; Schinkel, A.H. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest., 1996, 97, 1211-1218.
152. Yamaguchi, S.; Zhao, Y.L.; Nadai, M.; Yoshizumi, H.; Cen, X.; Torita, S.; Takagi, K.; Takagi, K.; Hasegawa, T. Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob. Agents Chemother., 2006, 50, 80-87.
153. Sasaki, M.; Suzuki, H.; Ito, K.; Abe, T.; Sugiyama, Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting
154. Cui, Y.; Konig, J.; Keppler, D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol., 2001, 60, 934-943.
155. Matsushima, S.; Maeda, K.; Kondo, C.; Hirano, M.; Sasaki, M.; Suzuki, H.; Sugiyama, Y. Identification of the hepatic efflux transporters of organic anions using double transfected MDCKII cells expressing human OATP1B1/MRP2, OATP1B1/MDR1 and OATP1B1/BCRP. J. Pharmacol. Exp. Ther., 2005.
156. Schwab, D.; Fischer, H.; Tabatabaei, A.; Poli, S.; Huwyler, J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem., 2003, 46, 1716-1725.
157. Schinkel, A.H.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; Borst, P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest., 1995, 96, 1698-1705.
158. Baltes, S.; Gastens, A.M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Loscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 2007, 52, 333-346.
159. Feng, B.; Mills, J.; Davidson, R.; Mireles, R.; Janiszewski, J.; Troutman, M.; de Morais, S. In vitro P-glycoprotein Assays to Predict the in vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System. Drug Metab. Dispos., 2008, 36, 268-275.
160. Gao, J.; Murase, O.; Schowen, R.L.; Aube, J.; Borchardt, R.T. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res., 2001, 18, 171-176.
161. Yamazaki, M.; Neway, W.E.; Ohe, T.; Chen, I.; Rowe, J.F.; Hochman, J.H.; Chiba, M.; Lin, J.H. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther., 2001, 296, 723-735.
162. Sasaki, M.; Suzuki, H.; Aoki, J.; Ito, K.; Meier, P.J.; Sugiyama, Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol., 2004, 66, 450-459,
163. Doran, A.; Obach, R.S.; Smith, B.J.; Hosea, N.A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L.M.; Gibbs, J.P.; Gibbs, M.A.; Hatch, H.; Hop, C.E.; Kasman, I.N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F.M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D.K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J.W.; Venkatakrishnan, K.; Walens, G.; Wang, E.Q.; Wong, D.; Yasgar, A.S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos., 2005, 33, 165-174.
164. Eneroth, A.; Astrom, E.; Hoogstraate, J.; Schrenk, D.; Conrad, S.; Kauffmann, H.M.; Gjellan, K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci., 2001, 12, 205-214.
165. Eckhardt U., Schroeder A., Stieger B., Hochli M., Landmann L., Tynes R., Meier P.J., Hagenbuch B. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am. J. Physiol., 1999, 276, G1037-G1042.
166. Cvetkovic, M.; Leake, B.; Fromm, M.F.; Wilkinson, G.R.; Kim, R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos., 1999, 27, 866-871.
167. Sekine, T.; Cha, S.H.; Hosoyamada, M.; Kanai, Y.; Watanabe, N.; Furuta, Y.; Fukuda, K.; Igarashi, T.; Endou, H. Cloning, functional characterization, and localization of a rat renal Na+-dicarboxylate transporter. Am. J. Physiol., 1998, 275, F298-F305.
168. Cha, S.H.; Sekine, T.; Fukushima, J.I.; Kanai, Y.; Kobayashi, Y.; Goya, T.; Endou, H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol., 2001, 59, 1277-1286.
169. Wang, E.J.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab. Dispos., 2000, 28, 522-528.
170. Tiberghien F.; Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs., 1996, 7, 568-578.
171. Kalgutkar. A.S.; Feng, B.; Nguyen, H.T.; Frederick, K.S.; Campbell, S.D.; Hatch, H.L.; Bi, Y.A.; Kazolias, D.C.; Davidson, R.E.; Mireles, R.J.; Duignan, D.B.; Choo, E.F.; Zhao, S.X. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy) -pyridine-3-carbonyl]-amino}-methy l)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab. Dispos., 2007, 35, 2111-2118.
172. Lohmann, C.; Gelius, B.; Danielsson, J.; Skoging-Nyberg, U.; Hollnack, E.; Dudley, A.; Wahlberg, J.; Hoogstraate, J.; Gustavsson, L. Scintillation proximity assay for measuring uptake by the human drug transporters hOCT1, hOAT3, and hOATP1B1. Ana., Biochem., 2007, 366, 117-125.
173. LeCluyse, E.L.; Bullock, P.L.; Parkinson, A.; Hochman, J.H. Cultured rat hepatocytes. Pharm. Biotechnol., 1996, 8, 121-159.
174. Houle. R.; Raoul, J.; Levesque, J.F.; Pang, K.S.; Nicoll-Griffith, D.A.; Silva, J.M. Retention of transporter activities in cryopreserved, isolated rat hepatocytes. Drug Metab. Dispos., 2003, 31, 447-451.
175. Jorgensen, L.; Van Beek, J.; Lund, S.; Schousboe, A.; Badolo, L. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur. J. Pharm. Sci., 2007, 30, 181-189.
176. Ishigami, M.; Tokui, T.; Komai, T.; Tsukahara, K.; Yamazaki, M.; Sugiyama, Y. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm. Res., 1995, 12, 1741-1745.
177. Petzinger, E.; Fuckel, D. Evidence for a saturable, energydependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. Eur. J. Pharmacol., 1992, 213, 381-391.
178. Bi, Y.A.; Kazolias, D.; Duignan, D.B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos., 2006, 34, 1658-1665.
179. Ghibellini, G.; Vasist, L.S.; Leslie, E.M.; Heizer, W.D.; Kowalsky, R.J.; Calvo, B.F.; Brouwer, K.L. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin. Pharmacol. Ther., 2007, 81, 406-413.
180. Liu, X.; LeCluyse, E.L.; Brouwer, K.R.; Lightfoot, R.M.; Lee, J.I.; Brouwer, K.L. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther., 1999, 289, 1592-1599.
181. Liu, X.; LeCluyse, E.L.; Brouwer, K.R.; Gan, L.S.; Lemasters, J.J.; Stieger, B.; Meier P.J.; Brouwer, K.L. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol., 1999, 277, G12-G21.
182. Liu, X.; Chism, J.P.; LeCluyse, E.L.; Brouwer, K.R.; Brouwer, K.L. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos., 1999, 27, 637-644.
183. Wang, E.J.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem. Biophys. Res. Commun., 2001, 289, 580-585.
184. Robey, R.W.; Medina-Perez, W.Y.; Nishiyama, K.; Lahusen, T.; Miyake, K.; Litman, T.; Senderowicz, A.M.; Ross, D.D.; Bates, S.E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 2001, 7, 145-152.
185. Schuetz, E.G.; Schinkel, A.H.; Relling, M.V.; Schuetz, J.D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA, 1996, 93, 4001-4005.
186. Perloff, M.D.; Von Moltke, L.L.; Marchand, J.E.; Greenblatt, D.J. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J.Pharm. Sci., 2001, 90, 1829-1837.
187. Kast, H.R.; Goodwin, B.; Tarr, P.T.; Jones, S.A.; Anisfeld, A.M.; Stoltz, C.M.; Tontonoz, P.; Kliewer, S.; Willson, T.M.; Edwards, P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem., 2002, 277, 2908-2915.
188. Guo, G.L.; Staudinger, J.; Ogura, K.; Klaassen, C.D. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol., 2002, 61, 832-839.
189. Chen, Y.; Tang, Y.; Wang, M.T.; Zeng, S.; Nie, D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res., 2007, 67, 10361-10367.
190. Grover, G.S.; Brayman, T.G.; Voorman, R.L.; Ware, J.A. Development of In vitro Methods to Predict Induction of CYP1A2 and CYP3A4 in Humans. Assay Drug Dev. Technol., 2007, 5(6), 793-804.
191. Schuetz, E.; Lan L.; Yasuda, K.; Kim, R.; Kocarek, T.A.; Schuetz, J.; Strom, S. Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol. Pharmacol., 2002, 62, 439-445.
192. Langer, T.; Eder, M.; Hoffmann, R.D.; Chiba, P.; Ecker, G.F. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Archiv. der. Pharmazie., 2004, 337, 317-327.
193. Khan, M.T.; Sylte, I. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules. Curr. Drug Discov. Technol., 2007, 4, 141-149.
194. Lave, T.; Parrott, N.; Grimm, H.P.; Fleury, A.; Reddy, M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica., 2007, 37, 1295-1310.
195. Chang, C.; Ekins, S.; Bahadduri, P.; Swaan, P.W. Pharmacophore-based discovery of ligands for drug transporters. Adv. Drug Deliv. Rev., 2006, 58, 1431-1450.
196. Ekins, S.; Ecker, G.F.; Chiba P.; Swaan, P.W. Future directions for drug transporter modelling. Xenobiotica., 2007, 37, 1152-1170.
197. Stephens, R.H.; Tanianis-Hughes, J.; Higgs, N.B.; Humphrey, M.; Warhurst, G. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J. Pharmacol. Exp. Ther., 2002, 303, 1095-1101.
198. Mallants, R.; Van Oosterwyck, K.; Van Vaeck, L.; Mols, R.; De Clercq, E.; Augustijns, P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica, 2005, 35, 1055-1066.
199. Kawahara, M.; Sakata, A.; Miyashita, T.; Tamai, I.; Tsuji, A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci., 1999, 88, 1281-1287
200. Tian, Q.; Zhang, J.; Tan, T.M.; Chan, E.; Duan, W.; Chan, S.Y.; Boelsterli, U.A.; Ho, P.C.; Yang, H.; Bian, J.S.; Huang, M.; Zhu, Y.Z.; Xiong, W.; Li, X.; Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res., 2005, 22, 1837-1853.
201. Zaher, H.; Khan, A.A.; Palandra, J.; Brayman, T.G.; Yu, L.; Ware, J.A. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm., 2006, 3, 55-61.
202. Kivisto, K.T.; Grisk, O.; Hofmann, U.; Meissner, K.; Moritz, K.U.; Ritter, C.; Arnold, K.A.; Lutjoohann, D.; von Bergmann, K.; Kloting, I.; Eichelbaum, M.; Kroemer, H.K. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug Metab. Dispos., 2005, 33, 1593-1596.
203. Yamazaki, M.; Kobayashi, K.; Sugiyama, Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats. Biopharm. Drug Dispos., 1996, 17, 645-659.
204. Luurtsema, G.; Molthoff, C.F.; Schuit, R.C.; Windhorst, A.D.; Lammertsma, A.A.; Franssen, E.J. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol., 2005, 32, 87-93.
205. Tian, X.; Li, J.; Zamek-Gliszczynski, M.J.; Bridges, A.S.; Zhang, P.; Patel, N.J.; Raub, T.J.; Pollack, G.M.; Brouwer, K.L. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother., 2007, 51, 3230-3234.
206. Lankas, G.R.; Cartwright, M.E. Umbenhauer, D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol., 1997, 143, 357-365.
207. Umbenhauer, D.R.; Lankas, G.R.; Pippert, T.R.; Wise, L.D.; Cartwright, M.E.; Hall, S.J.; Beare, C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol., 1997, 146, 88-94.
208. Pippert, T.R.; Umbenhauer, D.R. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J. Biochem. Mol. Toxicol., 2001, 15, 83-89.
209. Mealey, K.L.; Northrup, N.C.; Bentjen, S.A. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc., 2003, 223, 1453-1455, 1434.
210. Roulet, A.; Puel, O.; Gesta, S.; Lepage, J.F.; Drag, M.; Soll, M.; Alvinerie, M.; Pineau, T. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol., 2003, 460, 85-91.
211. Hirohashi, T.; Suzuki, H.; Ito, K.; Ogawa, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Hepatic expression of multidrug resistanceassociated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol. Pharmacol., 1998, 53, 1068-1075.
212. Elferink, R.O.; Groen, A.K. Genetic defects in hepatobiliary transport. Biochim. Biophys. Acta., 2002, 1586, 129-145.
213. Jonker, J.W.; Wagenaar, E.; Van Eijl, S.; Schinkel, A.H. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell Biol., 2003, 23, 7902-7908.
214. Eraly, S.A.; Vallon, V.; Vaughn, D.A.; Gangoiti, J.A.; Richter, K.; Nagle, M.; Monte, J.C.; Rieg, T.; Truong, D.M.; Long, J.M.; Barshop, B.A.; Kaler, G.; Nigam, S.K. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem., 2006, 281, 5072-5083.
215. Schinkel, A.H.; Mayer, U.; Wagenaar, E.; Mol, C.A.; van Deemter, L.; Smit, J.J.; van der Valk, M.A.; Voordouw, A.C.; Spits, H.; van Tellingen, O.; Zijlmans, J.M.; Fibbe, W.E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 1997, 94, 4028-4033.
216. Smith, B.J.; Doran, A.C.; McLean, S.; Tingley, F.D.; 3rd, O'Neill, B.T.; Kajiji, S.M. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J. Pharmacol. Exp. Ther., 2001, 298, 1252-1259.
217. Zhang, L.; Strong, J.M.; Qiu, W.; Lesko, L.J.; Huang, S.M. Scientific perspectives on drug transporters and their role in drug interactionst. Mol. Pharm., 2006, 3, 62-69.
218. Tang-Wai, D.F.; Kajiji, S.; Di Capua, F.; de Graaf, D.; Roninson, I.B.; Gros, P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry, 1995, 34, 32-39.
219. Mizuno, N.; Suzuki, M.; Kusuhara, H.; Suzuki, H.; Takeuchi, K.; Niwa, T.; Jonker, J.W.; Sugiyama, Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl- 2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos., 2004, 32, 898-901.
220. Sahi, J. Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Expert Opin. Drug Metab. Toxicol., 2005, 1, 409-427.
221. Zhang, Y.; Bachmeier, C.; Miller, D.W. In vitro and in vivo models for assessing drug efflux transporter activity. Adv. Drug Deliv. Rev., 2003, 55, 31-51.
222. Xia, C.Q.; Milton, M.N.; Gan, L.S. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr. Drug Metab., 2007, 8, 341-363.
223. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55, 3-29.
224. Ayrton, A.; Morgan, P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica., 2001, 31, 469-497.
225. Chinn, L.W.; Kroetz, D.L. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol. Ther., 2007, 81, 265-269.
226. Ueda, K.; Cornwell, M.M.; Gottesman, M.M.; Pastan, I.; Roninson, I.B.; Ling, V.; Riordan, J.R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun., 1986, 141, 956-962.
227. Lockhart, A.C.; Tirona, R.G.; Kim, R.B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol. Cancer Ther., 2003, 2, 685-698.
228. Lum, B.L.; Gosland, M.P.; Kaubisch, S.; Sikic, B.I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy, 1993, 13, 88-109.
229. Roepe, P.D. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance? Curr. Pharm. Des., 2000, 6, 241-260.
230. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat., 2003, 6, 71-84.
231. Mealey, K.L. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther., 2004, 27, 257-264.
232. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther., 2004, 75, 13-33.
233. Bushman, F.; Landau, N.R.; Emini, E.A. New developments in the biology and treatment of HIV. Proc. Natl. Acad. Sci. USA, 1998, 95, 11041-11042.
234. Collier, A.C.; Coombs, R.W.; Schoenfeld, D.A.; Bassett, R.L.; Timpone, J.; Baruch, A.; Jones, M.; Facey, K.; Whitacre, C.; McAuliffe, V.J.; Friedman, H.M.; Merigan, T.C.; Reichman, R.C.; Hooper, C.; Corey, L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med., 1996, 334, 1011-1017.
235. Moyle, G.J. Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection. Curr. Opin. Infect Dis., 2000, 13, 19-25.
236. Romano, L.; Venturi, G.; Giomi, S.; Pippi, L.; Valensin, P.E.; Zazzi, M. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. J. Med. Virol., 2002, 66, 143-150.
237. Shibata, N.; Gao, W.; Okamoto, H.; Kishida, T.; Yoshikawa, Y.; Takada, K. In vitro and in vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. J. Pharm. Pharmacol., 2002, 54, 221-229.
238. Tomasselli, A.G.; Heinrikson, R.L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta., 2000, 1477, 189-214.
239. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996, 381, 661-666.
240. Choo, E.F.; Leake, B.; Wandel, C.; Imamura, H.; Wood, A.J.; Wilkinson, G.R.; Kim, R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos., 2000, 28, 655-660.
241. Fromm, M.F.; Kim, R.B.; Stein, C.M.; Wilkinson, G.R.; Roden, D.M. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation, 1999, 99, 552-557.
242. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.; Roden, D.M.; Wilkinson, G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 1998, 101, 289-294.
243. Aweeka, F.; Jayewardene, A.; Staprans, S.; Bellibas, S.E.; Kearney, B.; Lizak, P.; Novakovic-Agopian, T.; Price, R.W. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1 - infected patients with and without AIDS dementia complex. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1999, 20, 39-43.
244. Bachmeier, C.J.; Spitzenberger, T.J.; Elmquist, W.F.; Miller, D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res., 2005, 22, 1259-1268.
245. Rogers, R.C.; Sibai, B.M.; Whybrew, W.D. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am. J. Obstet. Gynecol., 1990, 162, 362-366.
246. Huisman, M.T.; Smit, J.W.; Schinkel, A.H. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Aids, 2000, 14, 237-242.
247. Huisman, M.T.; Smit, J.W.; Wiltshire, H.R.; Hoetelmans, R.M.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol., 2001, 59, 806-813.
248. Lee, C.G.; Gottesman, M.M.; Cardarelli, C.O.; Ramachandra, M.; Jeang, K.T.; Ambudkar, S.V.; Pastan, I.; Dey, S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry, 1998, 37, 3594-3601.
249. Huang, L.; Wring, S.A.; Woolley, J.L.; Brouwer, K.R.; Serabjit-Singh, C.; Polli, J.W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos., 2001, 29, 754-760.
250. Bardsley-Elliot A.; Plosker, G.L. Nelfinavir: an update on its use in HIV infection. Drugs, 2000, 59, 581-620.
251. Polli, J.W.; Jarrett, J.L.; Studenberg, S.D.; Humphreys, J.E.; Dennis, S.W.; Brouwer, K.R.; Woolley, J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res., 1999, 16, 1206-1212.
252. Bhutta, T.I.; Tahir, K.I. Loperamide poisoning in children. Lancet, 1990, 335, 363.
253. McCowat, L.A.; Cutting, W.A.; Steinke, D.; MacDonald, T.M. Treating diarrhoea. Children deserve special attention. BMJ (Clinical research ed, 1997, 315, 1378-1379; author reply 1379-1380.
254. Sadeque, A.J.; Wandel, C.; He, H.; Shah, S.; Wood, A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther., 2000, 68, 231-237.
255. Drescher S.; Glaeser H.; Murdter T.; Hitzl M.; Eichelbaum M.; Fromm, M.F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther., 2003, 73, 223-231.
256. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; von Richter, O.; Zundler, J.; Kroemer, H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 1999, 104, 147-153.
257. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cations transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 2007, 24, 1227-1251.
258. Chen, C.; Mireles, R.J.; Campbell, S.D.; Lin, J.; Mills, J.B.; Xu, J.J.; Smolarek, T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos., 2005, 33, 537-546.
259. Backman, J.T.; Luurila H.; Neuvonen, M.; Neuvonen, P.J. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther., 2005, 78, 154-167.
260. Bailey, D.G.; Dresser, G.K.; Leake, B.F.; Kim, R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther., 2007, 81, 495-502.
261. Dresser, G.K.; Bailey, D.G.; Leake, B.F.; Schwarz, U.I.; Dawson, P.A.; Freeman, D.J.; Kim, R.B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 2002, 71, 11-20.
262. Paine, M.F.; Widmer, W.W.; Hart, H.L.; Pusek, S.N.; Beavers, K.L.; Criss, A.B.; Brown, S.S.; Thomas, B.F.; Watkins, P.B. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr., 2006, 83, 1097-1105.
263. van Heek, M.; Farley, C.; Compton, D.S.; Hoos, L.; Alton, K.B.; Sybertz, E.J.; Davis, H.R.; Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol., 2000, 129, 1748-1754.
264. Oswald, S.; Haenisch, S.; Fricke, C.; Sudhop, T.; Remmler, C.; Giessmann, T.; Jedlitschky, G.; Adam, U.; Dazert, E.; Warzok, R.; Wacke, W.; Cascorbi, I.; Kroemer, H.K.; Weitschies W.; von Bergmann K., Siegmund W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin. Pharmacol. Ther., 2006, 79, 206-217.
265. Ezzet, F.; Krishna, G.; Wexler, D.B.; Statkevich, P.; Kosoglou, T.; Batra, V.K. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin. Ther., 2001, 23, 871-885.
266. Garcia-Calvo, M.; Lisnock, J.; Bull, H.G.; Hawes, B.E.; Burnett, D.A.; Braun, M.P.; Crona, J.H.; Davis, H.R.; Jr.; Dean, D.C.; Detmers, P.A.; Graziano, M.P.; Hughes, M.; Macintyre, D.E.; Ogawa, A.; O'Neill, K.A.; Iyer, S.P.; Shevell, D.E.; Smith, M.M.; Tang, Y.S.; Makarewicz, A.M.; Ujjainwalla, F.; Altmann, S.W.; Chapman, K.T.; Thornberry, N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA, 2005, 102, 8132-8137.
267. Oswald, S.; Westrup, S.; Grube, M.; Kroemer, H.K.; Weitschies, W.; Siegmund, W. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J. Pharmacol. Exp. Ther., 2006, 318, 1293-1299.
268. Oswald, S.; Giessmann, T.; Luetjohann, D.; Wegner, D.; Rosskopf, D.; Weitschies. W.; Siegmund, W. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin. Pharmacol. Ther., 2006, 80, 477-485.
269. de Jong, F.A.; Scott-Horton, T.J.; Kroetz, D.L.; McLeod, H.L.; Friberg, L.E.l.; Mathijssen, R.H.; Verweij, J.; Marsh, S.; Sparreboom, A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther., 2007, 81, 42-49.
270. Toffoli, G.; Cecchin, E.; Corona, G.; Russo, A.; Buonadonna, A.; D'Andrea, M.; Pasetto, L.M.; Pessa, S.; Errante, D.; De Pangher, V.; Giusto, M.; Medici, M.; Gaion, F.; Sandri, P.; Galligioni, E.; Bonura, S.; Boccalon, M.; Biason, P.; Frustaci, S. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 2006, 24, 3061-3068.
271. Xie, R.; Mathijssen, R.H.; Sparreboom, A.; Verweij, J.; Karlsson, M.O. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol. Ther., 2002, 72, 265-275.